Straumann Group (STMN) Q4 2025 earnings summary

Executive summary

• Achieved CHF 2.6 billion in revenue for 2025, up 8.9% organically, with continued market share gains and profitability in line with guidance, despite currency and tariff headwinds.

• Delivered 7.3 million smiles in 2025, an increase of 600,000 from the previous year, reflecting growth in both implants and clear aligner cases.

• Record product launches and innovation, including over 1 million iEXCEL implants sold, SIRIOS X3 scanner, and digital workflow expansion, drove market adoption.

• High employee engagement score of 80, supporting a strong performance culture and agility.

• Sustainability progress included a 17% reduction in Scope 1 and 2 CO2 emissions since 2021 and 98.5% renewable electricity usage.

Financial highlights

• Revenue of CHF 2.6 billion, up 8.9% organically and 4.1% in Swiss francs, with a CHF 100 million negative currency impact.

• Core gross profit margin at 70.1%, supported by product mix and scale, partially offset by tariffs and Shanghai ramp-up.

• Core EBIT margin reached 25.2% (reported), 26.5% (constant currency), with efficiency gains and cost-saving measures.

• Free cash flow totaled CHF 290 million (11.1% of revenue), with CapEx at CHF 223 million, marking the end of a major investment cycle.

• Proposed dividend increased to CHF 1.00 per share, a 5% rise, with a payout ratio of about 33%.

Outlook and guidance

• 2026 outlook projects high single-digit organic revenue growth and 30–60 basis points EBIT margin expansion at constant 2025 FX rates.

• Growth in 2026 anticipated to be more weighted toward the second half, especially in Asia-Pacific and China due to VBP timing.

• CapEx and non-core items expected to decrease in 2026, supporting stronger free cash flow.

• Business model expected to remain resilient amid ongoing market volatility and regulatory challenges.